Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Cancer Res. 2017 Nov 8;78(3):809–816. doi: 10.1158/0008-5472.CAN-17-2995

Figure 4.

Figure 4

Combined effects of baseline IDO biomarkers and post-RT change with survival and tumor progression. Patients were stratified into 4 groups according to the medians of pre-RT K:T ratio (baseline immune activity) and post/pre kynurenine (change of immune activity). Group 1: favorable baseline and favorable change; Group 2: unfavorable baseline and favorable change; Group 3: favorable baseline and unfavorable change; Group 4: unfavorable baseline and change. (A) Comparison of overall survival (OS) in 4 groups, Group 1 showing extremely long-term OS. (B) Comparison of progression free survival (PFS) in 4 groups.

(C) Comparison of tumor local/regional and distant progressions in 4 groups. The favorable baseline (Groups 1 and 3) corresponded to less local/regional progression, while Group 2 had 0% distant progression.

(D) Comparison of OS for patients developed distant metastasis for Groups 1, 3 and 4.